HUE045626T2 - Imidazo[4,5-C]piridin alapú SSAO inhibitorok - Google Patents

Imidazo[4,5-C]piridin alapú SSAO inhibitorok

Info

Publication number
HUE045626T2
HUE045626T2 HUE15770604A HUE15770604A HUE045626T2 HU E045626 T2 HUE045626 T2 HU E045626T2 HU E15770604 A HUE15770604 A HU E15770604A HU E15770604 A HUE15770604 A HU E15770604A HU E045626 T2 HUE045626 T2 HU E045626T2
Authority
HU
Hungary
Prior art keywords
imidazo
ssao inhibitors
pyridine derived
pyridine
derived
Prior art date
Application number
HUE15770604A
Other languages
English (en)
Inventor
Max Espensen
Lee Patient
Edward Savory
Original Assignee
Proximagen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Llc filed Critical Proximagen Llc
Publication of HUE045626T2 publication Critical patent/HUE045626T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
HUE15770604A 2014-09-17 2015-09-17 Imidazo[4,5-C]piridin alapú SSAO inhibitorok HUE045626T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1416446.1A GB201416446D0 (en) 2014-09-17 2014-09-17 New enzyme inhibitor compounds

Publications (1)

Publication Number Publication Date
HUE045626T2 true HUE045626T2 (hu) 2020-01-28

Family

ID=51869761

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15770604A HUE045626T2 (hu) 2014-09-17 2015-09-17 Imidazo[4,5-C]piridin alapú SSAO inhibitorok

Country Status (15)

Country Link
US (1) US10065954B2 (hu)
EP (1) EP3194388B1 (hu)
JP (1) JP6556838B2 (hu)
CN (1) CN107074854B (hu)
AU (1) AU2015316610B2 (hu)
BR (1) BR112017005314A2 (hu)
CA (1) CA2961422A1 (hu)
DK (1) DK3194388T3 (hu)
ES (1) ES2745824T3 (hu)
GB (1) GB201416446D0 (hu)
HU (1) HUE045626T2 (hu)
IL (1) IL251164B (hu)
PL (1) PL3194388T3 (hu)
PT (1) PT3194388T (hu)
WO (1) WO2016042331A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201416446D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
CN108148066A (zh) * 2017-12-23 2018-06-12 广东赛博科技有限公司 含异丙哌嗪和哌嗪三唑类结构化合物、制备方法及其用途
CN107936028A (zh) * 2017-12-23 2018-04-20 广东赛博科技有限公司 一种哌嗪三唑类化合物、制备方法及其用途
CN108003170A (zh) * 2017-12-23 2018-05-08 广东赛博科技有限公司 含吗啉和哌嗪三唑类衍生物及其用途
CN108003167A (zh) * 2017-12-23 2018-05-08 广东赛博科技有限公司 乙丙哌嗪的哌嗪三唑结构化合物及其用途
CN107936026A (zh) * 2017-12-23 2018-04-20 广东赛博科技有限公司 三唑类ssao抑制剂、制备方法及其用途
CN108084191A (zh) * 2017-12-23 2018-05-29 广东赛博科技有限公司 一种三唑类ssao抑制剂、制备方法及其用途
CN108084190A (zh) * 2017-12-23 2018-05-29 广东赛博科技有限公司 哌嗪三唑类ssao抑制剂、制备方法及其用途
CN108003169A (zh) * 2017-12-23 2018-05-08 广东赛博科技有限公司 一种含吗啉和哌嗪三唑类化合物及其用途
CN108164533A (zh) * 2017-12-23 2018-06-15 广东赛博科技有限公司 含胺基苯的哌嗪三唑结构的化合物及其用途
CN108084189A (zh) * 2017-12-23 2018-05-29 广东赛博科技有限公司 含氟苯和哌嗪三唑类化合物、制备方法及其用途
CN107936027A (zh) * 2017-12-23 2018-04-20 广东赛博科技有限公司 含哌嗪基和哌嗪三唑类结构化合物、制备方法及其用途
CN108003166A (zh) * 2017-12-23 2018-05-08 广东赛博科技有限公司 含哌嗪基和哌嗪三唑类结构化合物、制备方法及其用途
WO2021222308A1 (en) * 2020-04-28 2021-11-04 Metacrine, Inc. Ssao inhibitors for the treatment of disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038153A1 (en) * 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
KR20060073929A (ko) 2003-08-08 2006-06-29 라 졸라 파마슈티칼 컴파니 질환 치료에 유용한 세미카르바지드 민감성 아민옥시다제(ｓｓａｏ) 및 ｖａｐ-1 매개 유착의 억제제
WO2005023246A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
US20070293548A1 (en) 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
CN102232073B (zh) * 2008-09-16 2014-10-29 普罗克西梅根有限公司 Ssao活性抑制剂
JP5613671B2 (ja) * 2008-09-16 2014-10-29 プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． 新規化合物ｉｉ
US20120010188A1 (en) 2008-12-04 2012-01-12 Promimagen Ltd. Imidazopyridine Compounds
US9593108B2 (en) 2009-04-06 2017-03-14 Ptc Therapeutics, Inc. Compounds and methods for antiviral treatment
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
IN2014DN01883A (hu) 2011-09-14 2015-05-15 Proximagen Ltd
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201304527D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201404498D0 (en) * 2014-03-13 2014-04-30 Proximagen Ltd New compounds
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
GB201416444D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New compounds
GB201416446D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds

Also Published As

Publication number Publication date
DK3194388T3 (da) 2019-09-23
PT3194388T (pt) 2019-09-27
EP3194388A1 (en) 2017-07-26
ES2745824T3 (es) 2020-03-03
IL251164A0 (en) 2017-04-30
EP3194388B1 (en) 2019-08-14
IL251164B (en) 2020-10-29
GB201416446D0 (en) 2014-10-29
US10065954B2 (en) 2018-09-04
CN107074854B (zh) 2019-07-19
US20170362218A1 (en) 2017-12-21
PL3194388T3 (pl) 2019-12-31
JP6556838B2 (ja) 2019-08-07
BR112017005314A2 (pt) 2017-12-05
AU2015316610B2 (en) 2019-05-30
JP2017528493A (ja) 2017-09-28
CN107074854A (zh) 2017-08-18
CA2961422A1 (en) 2016-03-24
WO2016042331A1 (en) 2016-03-24
AU2015316610A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
IL251164A0 (en) Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao
GB201615282D0 (en) Tankyrase inhibitors
HK1225723A1 (zh) 取代的咪唑並[1，2-a]吡啶甲酰胺及其用途
IL251166B (en) Imidazo–[4,5–c]pyridine derivatives as inhibitors of ssao
AU358949S (en) Armrest
HK1255804A1 (zh) 作為雙重dyrk1/clk1抑制劑的新的咪唑並[4，5-b]吡啶衍生物
HRP20182016T1 (hr) Derivati etinila
ZA201900113B (en) Ethynyl derivatives
HK1246790A1 (zh) 乙炔基衍生物
DK3330264T3 (en) Pyridin substitueret 2-aminopyridin proteinkinase-inhibitorkrystal
HK1249096A1 (zh) 乙炔基衍生物
EP3265170A4 (en) Probe stimulator
GB201413671D0 (en) Seating